Ty Gluckman, M.D., says missed lipid tests and clinical inertia, not prior authorization, are now the main barriers to reaching LDL goals.
News|Articles|October 1, 2006
Valsartan appears more effective than amlodipine in preventing HF, diabetes in patients with hypertension
An angiotensin receptor blocker (ARB) valsartan-based regimen offered advantages over a calcium channel blocker (CCB) amlodipine-based regimen in preventing heart failure (HF) and diabetes in patients with hypertension, according to results of an analysis published in Hypertension.
Advertisement
Advertisement
Related to this article
AI analyzes single-lead ECGs from sleep studies to predict atrial fibrillation, heart failure, and mortality risk, enabling scalable cardiovascular disease screening.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Teen boys with obesity and lower baseline fitness were less likely to see MASLD resolve during a lifestyle program, a Belgian study found.
MassHealth's Katelyn Meyer, Pharm.D., says mandatory coverage, young patients and an unpredictable FDA make planning for new specialty drugs a challenge.
A truly transparent PBM arrangement starts with full disclosure of direct and indirect compensation.
The rule requires pharmacy benefit managers to disclose rebates and discounts, money made from spread pricing and incentives for formulary placement.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Labor Department rule ushers in a new era of PBM transparency for self-insured employers
2
HIV pipeline shifts toward weekly, monthly and twice-yearly dosing
3
The ripple effects of Medicare’s maximum fair price with Hiva Pourarsalan, Pharm.D. | AMCP Nexus 2026
4
What employers should demand from a truly transparent PBM
5